Gordon Dougan

Gordon Dougan
Institutions
Alma mater University of Sussex[1]
Thesis An Analysis of the Structure and Function of Plasmid ColE1 (1977)
Notable awards
Website
www.sanger.ac.uk/research/faculty/gdougan

Professor Gordon Dougan is Head of Pathogen Research and a member of the Board of Management at the Wellcome Trust Sanger Institute (WTSI) in Cambridge, United Kingdom.[4] He is also an Honorary Professor at the University of Cambridge and a Fellow of Wolfson College, Cambridge. During his career, Dougan has pioneered work on enteric diseases and been heavily involved in the movement to improve vaccine usage in developing countries. In this regard he was recently voted as one of the top ten most influential people in the vaccine world by people working in the area.[5]

Education

He was educated in his home town of Scunthorpe in England, attending Henderson Avenue Junior School, Scunthorpe Grammar School and John Leggott Sixth Form College. He graduated with a degree in Biochemistry and received his Ph.D. from the University of Sussex. Gordon completed postdoctoral research at the University of Washington (Seattle) in the laboratory of Professor Stanley Falkow.

Research

Dougan's research team studies enteric pathogens with a strong emphasis on basic pathogenic mechanisms and immunology.[6][7][8][9][10][11][12][13][14] He has a particular interest in using genomics to study host/pathogens interactions, in particular using Salmonella enterica serovar Typhi, the cause of typhoid. He has extensive experience working both in industry and in academia. Before moving to the WTSI he was the Director of the Centre for Molecular Microbiology and Infection at the Imperial College London and a Professor of Physiological Biochemistry. There he was responsible for securing multimillion-pound funding for a new building in Kensington and providing infrastructure for the science.

Career

Throughout his career Dougan has served as a referee, advisor and consultant for numerous institutions, universities, boards, committees and other organizations. He was a trustee of the International Vaccine Institute in Korea and has worked with other global agencies including the World Health Organisation and the Global Alliance for Vaccine and Innovations (now GAVI Alliance). He was elected a Fellow of the Academy of Medical Sciences in 2002,[15] is a member of the European Molecular Biology Organisation and was elected a Fellow of the Royal Society in 2012.[16]

Dougan was a lecturer in the Moyne Institute in Trinity College, Dublin and then worked for over ten years in industry developing vaccines and novel drugs at the Wellcome Foundation (now GSK). He has participated in early and late clinical studies on several vaccines and is an expert in vaccinology/pathogenic mechanisms, specialising on the immunology of mucosal vaccines and molecular basis of infection. He has been Chair of the Novartis Vaccines & Diagnostics Scientific Advisory Board and has spun out a number of companies. He has published over 400 research papers, edited several books and has sat on the editorial boards of a number of prestigious journals.[9][17]

Awards and honours

Dougan was elected a Fellow of the Royal Society in 2012. His nomination reads:

“ Gordon Dougan is distinguished through his investigations into how bacteria interact with and stimulate the mucosal surfaces of the body during infection. His work has focused on bacterial pathogens, principally Salmonella Typhi and other enteric bacteria and has exploited genetic manipulation of both the host and pathogen. He has made important contributions to basic studies on the molecular basis of the infection process, genomics and to the development of practical vaccines.[2] ”

He was elected a member of the European Molecular Biology Organization (EMBO) in 2011.[3]

Personal life

He has been a lifelong supporter of Scunthorpe United and is a keen beekeeper.

References

  1. 1 2 DOUGAN, Prof. Gordon. Who's Who. 2014 (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. (subscription required)
  2. 1 2 http://royalsociety.org/people/gordon-dougan/
  3. 1 2 "The EMBO Pocket Directory" (PDF). European Molecular Biology Organization. Archived from the original (PDF) on 2015-03-16.
  4. ↑ www-core (Web Team) (2013-05-24). "Professor Gordon Dougan - Wellcome Trust Sanger Institute". Sanger.ac.uk. Retrieved 2013-06-06.
  5. ↑ Smale, Freya. "Who are the most influential people in vaccines?". Blogs.terrapinn.com. Retrieved 2013-06-06.
  6. ↑ Rodriguez, A.; Vigorito, E.; Clare, S.; Warren, M. V.; Couttet, P.; Soond, D. R.; Van Dongen, S.; Grocock, R. J.; Das, P. P.; Miska, E. A.; Vetrie, D.; Okkenhaug, K.; Enright, A. J.; Dougan, G.; Turner, M.; Bradley, A. (2007). "Requirement of bic/microRNA-155 for Normal Immune Function". Science. 316 (5824): 608–11. doi:10.1126/science.1139253. PMC 2610435Freely accessible. PMID 17463290.
  7. ↑ Maloy, K. J.; Salaun, L.; Cahill, R.; Dougan, G.; Saunders, N. J.; Powrie, F. (2002). "CD4+CD25+ TR Cells Suppress Innate Immune Pathology Through Cytokine-dependent Mechanisms". Journal of Experimental Medicine. 197 (1): 111–9. doi:10.1084/jem.20021345. PMC 2193798Freely accessible. PMID 12515818.
  8. ↑ Frankel, G.; Phillips, A. D.; Rosenshine, I.; Dougan, G.; Kaper, J. B.; Knutton, S. (1998). "Enteropathogenic and enterohaemorrhagic Escherichia coli : More subversive elements". Molecular Microbiology. 30 (5): 911–921. doi:10.1046/j.1365-2958.1998.01144.x.
  9. 1 2 Gordon Dougan's publications indexed by the Scopus bibliographic database, a service provided by Elsevier. (subscription required)
  10. ↑ Mutreja, A.; Kim, D. W.; Thomson, N. R.; Connor, T. R.; Lee, J. H.; Kariuki, S.; Croucher, N. J.; Choi, S. Y.; Harris, S. R.; Lebens, M.; Niyogi, S. K.; Kim, E. J.; Ramamurthy, T.; Chun, J.; Wood, J. L. N.; Clemens, J. D.; Czerkinsky, C.; Nair, G. B.; Holmgren, J.; Parkhill, J.; Dougan, G. (2011). "Evidence for several waves of global transmission in the seventh cholera pandemic". Nature. 477 (7365): 462–465. doi:10.1038/nature10392.
  11. ↑ Okoro, C. K.; Kingsley, R. A.; Connor, T. R.; Harris, S. R.; Parry, C. M.; Al-Mashhadani, M. N.; Kariuki, S.; Msefula, C. L.; Gordon, M. A.; De Pinna, E.; Wain, J.; Heyderman, R. S.; Obaro, S.; Alonso, P. L.; Mandomando, I.; MacLennan, C. A.; Tapia, M. D.; Levine, M. M.; Tennant, S. M.; Parkhill, J.; Dougan, G. (2012). "Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa". Nature Genetics. 44 (11): 1215–1221. doi:10.1038/ng.2423.
  12. ↑ Zhou, Z; McCann, A; Weill, F. X.; Blin, C; Nair, S; Wain, J; Dougan, G; Achtman, M (2014). "Transient Darwinian selection in Salmonella enterica serovar Paratyphi a during 450 years of global spread of enteric fever". Proceedings of the National Academy of Sciences of the United States of America. 111 (33): 12199–204. doi:10.1073/pnas.1411012111. PMC 4143038Freely accessible. PMID 25092320.
  13. ↑ Achtman, M.; Wain, J.; Weill, F. O. X.; Nair, S.; Zhou, Z.; Sangal, V.; Krauland, M. G.; Hale, J. L.; Harbottle, H.; Uesbeck, A.; Dougan, G.; Harrison, L. H.; Brisse, S.; S. Enterica MLST Study Group (2012). Bessen, Debra E, ed. "Multilocus Sequence Typing as a Replacement for Serotyping in Salmonella enterica". PLOS Pathogens. 8 (6): e1002776. doi:10.1371/journal.ppat.1002776. PMC 3380943Freely accessible. PMID 22737074.
  14. ↑ www-core (Web team) (2013-01-30). "Microbial pathogenesis - Wellcome Trust Sanger Institute". Sanger.ac.uk. Retrieved 2013-06-06.
  15. ↑ "The Academy of Medical Sciences | Directory of Fellows". Acmedsci.ac.uk. Retrieved 2013-06-06.
  16. ↑ "Fellows of the". Royal Society. Retrieved 2013-06-06.
  17. ↑ "Gordon Dougan - PubMed - NCBI". Ncbi.nlm.nih.gov. 2013-03-25. Retrieved 2013-06-06.
This article is issued from Wikipedia - version of the 10/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.